24 September 2022
: Case report
Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Yassine Kilani

DOI: 10.12659/AJCR.937500
Am J Case Rep 2022; 23:e937500
Table 1. Complete blood count (CBC). The bicytopenia found at the patient’s previous admission progressed into pancytopenia in the setting of COVID-19. Note that the patient had normocytic anemia and thrombocytopenia 1 month prior to admission.
Range & unit | 2 months prior (Baseline) | 1 month prior (previous admission) | Day 1 | Day 3 | Day 5 | Day 7 | Day 9 | Day 11 | |
---|---|---|---|---|---|---|---|---|---|
Platelets | 150–450×10/mcL | 227 | 119 | 143 | 77 | 53 | 21 | 13 | 12 |
White blood cells | 4.80–10.80×10/mcL | 6.74 | 6.54 | 8.00 | 2.65 | 1.84 | 0.63 | 0.42 | 0.37 |
Red blood cells | 4.70–6.10×10/mcL | 4.10 | 3.21 | 3.18 | 2.62 | 3.66 | 2.81 | 2.19 | 2.51 |
Hemoglobin | 14.0–18.0 g/dL | 11.4 | 8.7 | 8.1 | 6.5 | 9.3 | 7.2 | 5.6 | 6.4 |
Hematocrit | 42.0–52.0% | 34.8 | 25.2 | 24.1 | 20.0 | 28.2 | 22.0 | 18.0 | 19.3 |
MCV | 80.0–99.0 fL | 84.9 | 78.5 | 75.8 | 76.3 | 77.0 | 78.3 | 82.2 | 76.9 |
MCH | 27.0–31.0 fL | 27.8 | 27.1 | 25.5 | 24.8 | 25.4 | 25.6 | 25.6 | 25.5 |
RDW | 12.0–15.0% | 13.8 | 15.2 | 17.1 | 17.2 | 17.2 | 17.2 | 17.3 | 17.4 |
Neutrophils | 44.0–70.0% | 64.5 | 47.2 | 48.9 | 49.5 | 22.3 | 6.4 | 11.8 | 16.2 |
Lymphocyte | 20.0–45.0% | 24.2 | 24.3 | 29.8 | 34.7 | 64.1 | 76.2 | 78.6 | 70.3 |
Monocyte | 2.0–10.0% | 22.8 | 27.1 | 20.0 | 14.7 | 10.9 | 9.5 | 4.8 | 8.1 |
Eosinophil | 1.0–4.0% | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Basophil | 0.2–1.8% | 0.4 | 0.5 | 0.3 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 |
Immature granulocytes | 0.0–0.2% | 0.7 | 0.9 | 1.0 | 1.1 | 1.6 | 7.9 | 4.8 | 5.4 |